PDO Screen is built upon the recent success of our organoid screening platform which led to the first oncology agent to be approved for clinical trials within 5 years of development. We have specially designed this screening platform to meet the growing demands for a cost-effective and clinically-relevant preclinical solution for drug screening and development.
With our years of experience in organoid technology for other areas of preclinical drug development, we provide a broad range of services for a wide variety of disease indications and tissue types to:
Fast-track your clinical candidate selection
NEWS AND INSIGHTS